1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics in the United States, July 2019 (p2)

Healthcare Analysis & Statistics in the United States, July 2019 (p2)

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Pharma Intelligence

All regions

data types

31-60 of about 300 reports

Rheumatoid Arthritis KOL Interview – New Jersey, US

Rheumatoid Arthritis KOL Interview – New Jersey, US

  • $ 599
  • Industry report
  • July 2019

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies fo ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
Trogarzo

Trogarzo

  • $ 10000
  • Industry report
  • July 2019

Trogarzo (ibalizumab; Theratechnologies/TaiMed Biologics) is a recombinant humanized monoclonal antibody approved for the treatment of HIV-1 infection. It targets the HIV-1 post-attachment process by binding ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical, Therapy
  • Countries : United States
Elafibranor

Elafibranor

  • $ 10000
  • Industry report
  • July 2019

Elafibranor (Genfit) is an oral peroxisome proliferator-activated receptor (PPAR) alpha-delta dual agonist. The medication activates PPAR-alpha and PPAR-delta, which control gene expression. Stimulating ...

  • Industries : Healthcare
  • Countries : United States, European Union
Aramchol

Aramchol

  • $ 10000
  • Industry report
  • July 2019

Aramchol (arachidyl amido cholanoic acid; Galmed) is a conjugate of cholic acid and arachidic acid, and belongs to the synthetic fatty acid bile acid conjugates (FABACs) family. Aramchol inhibits the live ...

  • Industries : Healthcare
  • Countries : United States, European Union
Cenicriviroc

Cenicriviroc

  • $ 10000
  • Industry report
  • July 2019

Cenicriviroc (Allergan/Takeda) is a potent immunomodulator that blocks the chemokine receptors-2/5 (CCR-2/5). CCR-2/5 have been linked to the inflammatory and fibrogenic pathways in non-alcoholic steatohepatitis ...

  • Industries : Healthcare
  • Countries : United States, European Union
Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

  • $ 4750
  • Industry report
  • July 2019

This report includes a discussion of leading products, new technologies, market forecasts, drivers and limiters, competitors, trends and opportunities in the nearly $1bn Prostate Cancer Diagnostics and ...

  • Industries : Cancer, Pathology, Diagnostics
  • Countries : United States, Japan
Juluca

Juluca

  • $ 10000
  • Industry report
  • June 2019

Juluca ([dolutegravir + rilpivirine]; ViiV Healthcare/Johnson and Johnson) is a single-tablet regimen approved in the US for the treatment of patients infected with HIV-1 who have achieved viral supp ...

  • Industries : Therapy
  • Countries : United States, European Union
Complera

Complera

  • $ 10000
  • Industry report
  • June 2019

Complera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Johnson and Johnson) is a single-tablet regimen for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Atripla

Atripla

  • $ 10000
  • Industry report
  • June 2019

Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Genvoya

Genvoya

  • $ 10000
  • Industry report
  • June 2019

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Stribild

Stribild

  • $ 10000
  • Industry report
  • June 2019

Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Japan Tobacco) is a single-tablet regimen for the treatment of HIV-1 infection. It is a co-formulation of marketed ...

  • Industries : Therapy
  • Countries : United States, European Union, Japan
Tivicay

Tivicay

  • $ 10000
  • Industry report
  • June 2019

Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Isentress

Isentress

  • $ 10000
  • Industry report
  • June 2019

Isentress (raltegravir; Merck and Co) is a twice-daily, unboosted integrase inhibitor (INI) that is used in combination with other antiretroviral drugs for treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
leronlimab

leronlimab

  • $ 10000
  • Industry report
  • June 2019

Leronlimab (CytoDyn) is a humanized monoclonal antibody directed against C-C chemokine receptor 5 (CCR5), which is a co-receptor required for the attachment and entry of CCR5-tropic HIV-1 viruses into ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, European Union
Dovato

Dovato

  • $ 10000
  • Industry report
  • June 2019

Dovato ([dolutegravir + lamivudine]; ViiV Healthcare) is a single-tablet regimen approved in the US for the treatment of HIV-1 infection in patients who are treatment-naïve. It is also being developed ...

  • Industries : Therapy
  • Countries : United States, European Union
Bladder Cancer KOL Interview – US

Bladder Cancer KOL Interview – US

  • $ 599
  • Industry report
  • May 2019

A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed.

  • Industries : Cancer, Pathology
  • Countries : United States
Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

  • $ 599
  • Industry report
  • May 2019

This reimbursement interview with a US key opinion leader (KOL) provides insight into pricing strategies, pricing barriers, and potential reimbursement criteria for non-alcoholic steatohepatitis thera ...

  • Industries : Healthcare
  • Countries : United States
Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

  • $ 599
  • Industry report
  • May 2019

This interview with a US key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies, diagnostic tools, and future treatment ...

  • Industries : Healthcare
  • Countries : United States
Surgical Heart Valve Management Products

Surgical Heart Valve Management Products

  • $ 4750
  • Industry report
  • May 2019

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the surgical heart valve repair (annuloplasty) systems, surgical heart valve replacement products, ...

  • Industries : Medical Device, Cardiovascular Devices
  • Countries : World, United States, Japan
General and Pelvic Endoscopic Surgery

General and Pelvic Endoscopic Surgery

  • $ 4750
  • Industry report
  • May 2019

This Meddevicetracker report provides an analysis of the market for general and pelvic endoscopic surgery products in the US, five major EU markets, Japan, and the rest of the world. Market segments covered ...

  • Industries : Endoscopic Device
  • Countries : World, United States, Japan
Global Market for Arthroscopy Products and Sports Medicine Implants (2019)

Global Market for Arthroscopy Products and Sports Medicine Implants (2019)

  • $ 4750
  • Industry report
  • April 2019

This Meddevicetracker report provides an analysis of the market for arthroscopy products (including visualization systems, fluid management equipment, and manual and powered instruments) and sports medicine/soft ...

  • Industries : Diagnostic Imaging
  • Countries : World, United States, European Union
Fetzima

Fetzima

  • $ 10000
  • Industry report
  • March 2019

Fetzima (levomilnacipran; Allergan) is a serotonin-norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) in the US.

  • Industries : Mental Health, Therapy, Pathology
  • Countries : United States
Cymbalta

Cymbalta

  • $ 10000
  • Industry report
  • March 2019

Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since ...

  • Industries : Pathology, Chronic Disease, Therapy, Mental Health
  • Countries : United States, Japan, European Union
Abilify/Abilify Maintena, Pharma Intelligence

Abilify/Abilify Maintena, Pharma Intelligence

  • $ 10000
  • Industry report
  • March 2019

Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Latuda

Latuda

  • $ 10000
  • Industry report
  • March 2019

Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the ...

  • Industries : Mental Health, Pathology
  • Countries : Japan, United States, Germany, Italy, Spain, United Kingdom
Seroquel/Seroquel XR, Pharma Intelligence

Seroquel/Seroquel XR, Pharma Intelligence

  • $ 10000
  • Industry report
  • March 2019

The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
SAGE-217

SAGE-217

  • $ 10000
  • Industry report
  • March 2019

SAGE-217 (oral brexanolone; SAGE Therapeutics/Shionogi) is a novel, next-generation positive allosteric modulator that selectively binds synaptic and extrasynaptic gamma-aminobutyric acid-A (GABA-A) receptors ...

  • Industries : Mental Health, Pathology
  • Countries : United States
Trintellix

Trintellix

  • $ 10000
  • Industry report
  • March 2019

Trintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder (MDD). The drug follows a successful line of antidepressants developed by ...

  • Industries : Mental Health, Therapy, Pathology
  • Countries : United States
Rexulti

Rexulti

  • $ 10000
  • Industry report
  • March 2019

Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Afinitor

Afinitor

  • $ 10000
  • Industry report
  • March 2019

Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on